title: [Use of zoledronic acid for lung cancer with bone metastases - a study on reossification of osteolytic bone metastases].
abstract: Lung cancer often induces osteolytic bone metastases, and skeletal-related events(SRE)such as bone pain or fracture decrease the quality of life and survival of the patient. Zoledronic acid(ZDA)suppresses osteoclastic changes and reduces the risk of SRE. Over the last 6 years, 84 lung cancer patients who had osteolytic bone metastases were medicated with ZDA in our hospital. Effective reossification was observed in 25%of them, and they obtained longer survival term and better performance status than did patients without effective reossification. ZDA enabled enforcement of aggressive anticancer therapy(radiation± chemotherapy)by reduction of SRE following reossification of osteolytic bone metastases, and contributed to better prognoses for lung cancer patients.
authors.affiliation: Dept. of Respiratory Medicine, Naga Municipal Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ikeda
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hayata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D011788:Quality of Life; D055815:Young Adult; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid